Biotech IP Focus McNeill PLLC specializes in biotech and pharma IP, offering comprehensive patent prosecution, opinions, portfolio management, and due diligence for acquirers, investors, and target companies. This deep life sciences focus presents a compelling value proposition for early-stage and growth biotech firms seeking strong IP strategy and monetization pathways. Opportunity: engage biotech startups and mid-market players needing robust IP protection and scalable portfolio development.

M&A Due Diligence The firm has substantial experience in due diligence and freedom-to-operate projects across acquiring companies, investors, and targets. This enables a fast, thorough IP risk assessment for M&A, licensing, and partnership opportunities. Opportunity: collaborate with corporate development teams and VC-backed portfolios to accelerate IP diligence and licensing readiness.

Portfolio Strategy McNeill provides a full spectrum of pre-litigation patent practice, including prosecution, opinions, portfolio management, appeals, and USPTO proceedings. This breadth supports clients across growth stages looking to optimize IP strategy, avoid litigation, and position assets for licensing or sale. Opportunity: offer integrated IP strategy packages to biotech firms planning funding rounds or strategic collaborations.

Diversity Advantage WBENC certification as a Women's Business Enterprise and a strong remote-friendly culture position McNeill as a diversity-driven supplier. This can appeal to large biopharma and tech companies with supplier-diversity programs and DEI goals. Opportunity: pursue procurement partnerships and government or corporate contracts that require diverse suppliers, leveraging remote delivery capabilities.

Reputation and Delivery Recognition as a top mid-size life sciences IP firm, combined with a modern tech stack and remote delivery model, supports high-quality, flexible client service. This can differentiate from larger firms and enable scalable, efficient engagements for biotech clients with distributed teams. Opportunity: pitch adaptable engagement models to mid-market biotech and pharma companies seeking specialized, responsive IP counsel.